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1st Editorial Decision 03 December 2010
Thank you for the submission of your research manuscript to EMBO reports. We have now received the enclosed referee reports on it.
As you will see, while all the referees agree that the study is potentially interesting, both referees 2 and 3 also point out that the novel finding that Sdc negatively regulates Robo/Slit signaling needs to be supported by additional evidence. Referee 2 indicates that endogenous Robo2 protein levels should be examined in the tracheal cells of both sdc mutants and in flies overexpressing sdc. Along these lines, referee 3 remarks that overexpression of sdc should result in a phenotype similar to slit or robo loss-of-function. Referee 2 also feels that Sdc expression needs to be demonstrated in dorsal branch cells of the trachea and that the genetic interaction between sdc and slit/robo should be confirmed by analyzing additional transheterozygous mutants.
Given these evaluations and the constructive referee comments, I would like to give you the opportunity to revise your manuscript, with the understanding that the referee concerns must be fully addressed and their suggestions (as detailed above and in their reports) taken on board. Acceptance of the manuscript will depend on a positive outcome of a second round of review and I should also remind you that it is EMBO reports policy to allow a single round of revision only and that, therefore, acceptance or rejection of the manuscript will depend on the completeness of your responses included in the next, final version of the manuscript.
I look forward to seeing a revised version of your manuscript when it is ready.
Yours sincerely,
Editor EMBO Reports REFEREE REPORTS:
Referee #1:
The manuscript describes new syndecan (syn) mutants and a thorough genetic analysis of syn function in the Drosophila respiratory organ. syn mutants show relatively mild and variable defects in a subset of the branch fusion events that interconnect the dorsal tracheal branches. The phenotypes of syn inactivation are rescued by syn re-expression in the tracheal cells indicating that Syn acts cell-autonomoulsy. This assay was also used to address the function of different domains of Syn in flies. The transmembarne domain and part of the ectodomain were dispensable for syndecan tracheal function.
The branch fusion phenotypes of syn mutants are similar to defects of robo2 and slit mutants, and reduction of the gene dosage of robo2 and slit ameliorates the defect of syn mutants. Inactivation of syn in salivary glands increases the production/stability of a Robo-GFP construct suggesting that syn may modulate its trafficking. Given the phylogenetic conservation of Robo and Syndecan and their abundant roles in organogenesis this finding would be of high interest.
There are a few points that need to be further clarified regarding the function of syn in Drosophila: 1) Does the rescue of the tracheal fusion defects result to a rescue of the "semilethal" phenotype of the mutants?
2) Does syndecan affect both Robo and Robo2? Figure 4E shows that UAS Robo-GFP is stabilized by inactivation of syndecan in the salivary gland suggesting that Syn can have a general role of Slit-Robo signaling. Is the migration of ganglionic tracheal branches and axons at the ventral midline affected in the syn mutants? If not how are the localized defects of syn mutants in tracheal dorsal branch migration explained? The authors need to discuss these issues.
3) The authors argue that syndecan plays a "critical" role in tracheal development. This is an overstatement given the mild defects in dorsal anastomoses formation that they present in figure 2A and B
Referee #2:
The important new point is the novel mechanism of HSPG activity (here Sdc) that is supposed to have a function in the stability of the receptor (here Robo2). However this point is only shown indirectly using over-expression in a different tissue and time . To my opinion it is critical to show the effect in the embryonic tracheal system (major point 2).
Review of Embo Reports manuscript: EMBOR-2010-34553V1
Drosophila syndecan regulates tracheal cell migration by suppressing Slit/Robo signaling by Schulz et al.
The manuscript describes the function of the Drosophila syndecan (sdc) gene during tracheal system development. The authors generated and analyzed a new sdc-specific mutant and investigated in addition the effect of sdc RNAi knock-down in the tracheal system identifying fusion defects of the dorsal branches of the opposing hemisegments. Furthermore, the authors show that sdc is required cell-autonomously within the tracheal system for this process and that the cytoplasmic part of Sdc is not required for Sdc activity in this process, indicating that Sdc does not function as a direct signal transducer. Furthermore, sdc interacts genetically with mutants of the Slit/Robo signal transduction pathway. In Robo over-expression experiments the authors detect a negative effect of sdc (suppression by sdc over-expression and enhancement in the sdc mutant), which would represent a new function of sdc in Slit/Robo signalling. The authors show a function of sdc for the Slit signal transduction pathway in a third tissue (axon guidance in the CNS and guidance of ventral muscles have been show in 2004) and the authors have published a "summary" of the RNAi induced tracheal phenotype in a NAR manuscript in 2009. However, the authors identified a completely new functional interaction of a HSPG in a signalling process. They suggest that Sdc regulates the expression/recycling of Robo2 rather than functioning as a co-receptor as shown before for Sdc in axon guidance and Dally-like for FGF-signalling in the tracheal system. This would represent an interesting novel aspect that would legitimate publication in EMBO Reports. However, to really prove this new role of Sdc the authors would have to include some more experiments (see below). First, I suggest analyzing the genetic interaction in a comparable way to the published papers that show a co-receptor function. Second, the authors would have to show the change in the endogenous Robo2 protein amounts in the tracheal cells both in the sdc mutant and in tracheal cells that over-express sdc to strengthen their mechanistic model.
Major points: 1) As the genetic interaction experiment is the key experiment the authors use to prove their model I think it is essential to include a classical genetic interaction experiment in addition: to investigate if sdc/+ does interact with slit/+ in double transheterozygous mutants. If they do not see an effect in this experiments they might want to test a zygotic mutant of sdc which still has the maternal contribution with heterozygous slit. The genetic analysis shown here does not exclude that slit is required for process that function in parallel. An additional point is minimal effect of robo2 in their experiment -the change is weak and seems not to be statistically relevant. This point is not discussed in the manuscript.
2) Much more convincing are the experiments of figure 4b: the effect of Sdc over-expression and loss-of-function for the Robo2 over-expression phenotypes. Englund et al have shown before that Slit functions as an attractive signal for the Robo2 expressing cells of the dorsal branch. It is interesting that the over-expression of Robo2 seems to be sufficient for a misguidance of the dorsal branch outgrowth. Here, it is clear that Sdc levels affect this gain-of-function phenotype. However, the mechanism of Sdc function is not clear. The authors show that higher levels of Robo-GFP can be observed in the salivary gland cells in sdc-RNAi treated 3rd instar larvae. To my opinion it is essential to investigate the levels of endogenous Robo2 in the dorsal branch in sdc mutants and in tracheal cells that over-express sdc. These experiments are easy to perform as there are good anti-Robo antibodies available (see figure 2 of Englund et al. 2002) .
3) If Sdc levels do affect Robo2 levels in the dorsal branch, do they also affect the levels of Robo in the remaining tracheal system -as shown by Englund et al.? Furthermore, it would highly interesting to investigate if the cytoplasmic domain of Sdc is important for that function. These experiments are easy to do -tracheal specific expression of sdc variants followed by an antibody staining .
Minor Points
In general the figure legends are extremely short and do not explain all details shown. Furthermore, at least in the combined pdf (text with figures) many panels are not labelled, I guess that this is an error from the generation of the pdf file. If the authors address the major points outlined below, I believe the manuscript could be accepted following re-review.
In this manuscript, Schulz et al provide the first evidence that the transmembrane HSPG Syndecan is involved in tracheal development in Drosophila, and that the role of Sdc in the migration and fusion of the dorsal branch cells is independent of Sdc's cytoplasmic domain. In addition, Schulz et al describe the generation of several novel Sdc mutations which represent the first alleles of Sdc that do not affect the neighboring gene sara. These are novel and significant findings, however, the data implicating Sdc as a negative regulator of slit/robo signaling do not appear to be robustly documented and at points seem to be contradictory (or at least inconsistent), and the manuscript does not provide convincing evidence for a genetic interaction with Rac. As a result of this ambiguity, the interest to the general molecular biology community might be somewhat limited.
Major points: 1. There are some unexplained inconsistencies in the data that make the interpretation of their results difficult. For example, in Figure 3B , the frequency of DA missing is approximately 4 using p127-Gal4 driving Sdc RNAi. Figure 3D also shows approximately 4 DA missing per larvae using Btl-Gal4(3-1) driving Sdc RNAi, just like the phenotype found in Sdc2639 ( Figure 3E .) However in Figure 4 , Btl-Gal4(1) results in only 1.8 DA missing per animal (panel A) or 3.4 missing per animal (panel G). Two important questions need to be addressed in manuscript. First, what is different about the Btl(3-1) used in Figure 3D and Btl(1) used in Figure 4 that would result in this difference in phenotype? Second, and more importantly, why are the frequencies of the defects in panel4A and 4G different when the experiment appears to be identical? This is an important point, because if the data from 4A were shown in panel 4G (which are described to the reader as the same experiment) it would indicate that rac is not a genetic interactor. 2. The model put forth, that Sdc acts as a negative regulator of Slit/Robo signaling (presumably via Sdc's ability to reduce Robo expression levels), is modestly supported by the experimental data, but additional experiments could help substantiate this model. For example, a UAS-Sdc construct would be hypothesized to enhance the UAS-Comm phenotype (as both would be acting to limit Robo cell surface expression). In addition, if Sdc is indeed suppressing the Slit/Robo signaling pathway, overexpression of Sdc should result in a phenotype similar to Slit or Robo. Both of these experiments would provide support for the proposed model. The data showing that Sdc RNAi generates a phenotype similar to Slit or Robo loss of funciton, suggests that Sdc works with Slit and Robo to enhance Slit/Robo signaling. This seemingly conflicting evidence may be due in part to the apparent similarity between robo loss-of-function and robo gain-of-function phenotypes (both of which result in an increase in the number of DA missing per animal). If the authors want to propose a model in which Sdc suppresses Slit/Robo signaling as the cause of the DB defects, substantial revisions of Figure 4 are necessary, for example, by proposing a mechanism by which Sdc and robo, despite having similar mutant phenotypes could somehow suppress each others' activities.
Minor Points: 1. In the x axis labels for Figure 3 , the font for delta gag and delta c is not correct. 2. The y-axis needs labels in Figure 4F . 3. In Figure legend 2C the authors state that "the arrow indicates the stub" but there is not an arrow in Figure 2C (or, perhaps it is in black in which case it should be in white). 4. In Figure legend 3C, the authors state that "Indicated are the absolute number or percentage of clones found in one of the three different DB cell types and whether these clones are part of a fused or unfused branch." This information is not in Figure 3C . 5. In Figure legend 4g , the authors describe the influence of Rac levels on the Sdc RNAi DB phenotype, stating that they tested it "in combination with the rac1J10, Rac2, mtl" alleles. Only "rac" is shown in this figure.
1st Revision -authors' response 10 May 2011
There are a few points that need to be further clarified regarding the function of syn in Drosophila:
1)
Does the rescue of the tracheal fusion defects result to a rescue of the "semilethal" phenotype of the mutants?
Answer: No, tracheal expression of Sdc does not rescue sdc semilethality. We quantified the elosion rate in sdc2639 mutants with tracheal Sdc rescue (btl-Gal4>UAS-Sdc) and included the data in Table I . The rate is completely unchanged when compared to sdc2639 mutant alone, although the fusion defects are completely rescued, demonstrating that the tracheal fusion defects are not causing lethality.
The following statement has been added to the text on page 7: "Tracheal expression of Sdc did not rescue the semilethality observed in the mutant (Table I) , indicating that the tracheal phenotype alone does not account for the lethality and that tracheal Sdc is not sufficient for full viability."
2)
Does syndecan affect both Robo and Robo2? Figure 4E shows that UAS Robo-GFP is stabilized by inactivation of syndecan in the salivary gland suggesting that Syn can have a general role of Slit-Robo signaling. Is the migration of ganglionic tracheal branches and axons at the ventral midline affected in the syn mutants? If not how are the localized defects of syn mutants in tracheal dorsal branch migration explained? The authors need to discuss these issues.
Answer: Indeed, the ganglionic branches are strongly affected in sdc mutant brains (both stalled and abnormally crossing the midline), very similar to Robo mutants. We added images of wildtype or sdc ganglionic branches expressing tracheal GFP to the supplemental data ( Supplementary Figure 1 ) and refer to that in the text page 4 and 10. A general role of Sdc in Slit/Robo signaling is possible, and this possiblity is stated in the discussion on page 10: " A general role for Sdc in Slit/Robo signaling is very likely, since the different Robo receptors share the same extracellular domain structure and differ in their cytoplasmic domain. Further investigation is required to test this idea."
3)
The authors argue that Syndecan plays a "critical" role in tracheal development. This is an overstatement given the mild defects in dorsal anastomoses formation that they present in figure 2A and B.
Answer: The text (discussion, page 11) has been changed to "a specific role in tracheal development." Referee #2:
The important new point is the novel mechanism of HSPG activity (here Sdc) that is supposed to have a function in the stability of the receptor (here Robo2). However this point is only shown indirectly using over-expression in a different tissue and time. To my opinion it is critical to show the effect in the embryonic tracheal system (major point 2).
Answer: We agree that one major point is that Sdc influences Robo levels, but the manuscripts also reports several other novel findings listed below: 1.the new role for Sdc in tracheal develoment, including cell-autonomy and core-protein analysis 2. a role for Sdc in cellular order and directed movement in vivo 3. the absence of a role of the cytoplasmic domain in that context Review of Embo Reports manuscript: EMBOR-2010-34553V1 Drosophila syndecan regulates tracheal cell migration by suppressing Slit/Robo signaling by Schulz et al.
Major points: 1)
As the genetic interaction experiment is the key experiment the authors use to prove their model I think it is essential to include a classical genetic interaction experiment in addition: to investigate if sdc/+ does interact with slit/+ in double transheterozygous mutants. If they do not see an effect in this experiments they might want to test a zygotic mutant of sdc which still has the maternal contribution with heterozygous slit. The genetic analysis shown here does not exclude that slit is required for process that function in parallel. An additional point is minimal effect of robo2 in their experiment -the change is weak and seems not to be statistically relevant. This point is not discussed in the manuscript.
Answer: We quantified DB fusion rates in sdc/slit and sdc/robo2 transheterozygotes as well as in sdc/sdc, slit and sdc/sdc, robo2 double mutants. We added the new data to Figure 4 (now Figure  4B) . The results confirm our RNAi results, that reduction of Slit dose (but not Robo2 dose) suppresses the sdc loss of function phenotype.
The effect of loss of one robo2 allele is now described more precisely on page 7: "Heterozygous loss of the receptor robo2 had a smaller effect, not reaching statistical significance"
2)
Much more convincing are the experiments of figure 4b: the effect of Sdc over-expression and loss-of-function for the Robo2 over-expression phenotypes. Englund et al have shown before that Slit functions as an attractive signal for the Robo2 expressing cells of the dorsal branch. It is interesting that the over-expression of Robo2 seems to be sufficient for a misguidance of the dorsal branch outgrowth. Here, it is clear that Sdc levels affect this gain-of-function phenotype. However, the mechanism of Sdc function is not clear. The authors show that higher levels of Robo-GFP can be observed in the salivary gland cells in sdc-RNAi treated 3rd instar larvae. To my opinion it is essential to investigate the levels of endogenous Robo2 in the dorsal branch in sdc mutants and in tracheal cells that over-express sdc. These experiments are easy to perform as there are good anti-Robo antibodies available (see figure 2 of Englund et al. 2002) .
Answer: We performed staining of wildtype, sdc mutant and Sdc overexpressing embryos with anti-Robo2 antibodies during stage 13/14 (in later stages the signal became too weak), but could not detect a clear change in anti-Robo2 signal intensity. We reasoned that this may be due to the fact that the changes in Robo levels are subtle, and thus diffcult to detect by imuunohistochemistry. In contrast GFP-tagged Robo would allow detection with higher sensitivity. In order to examine the issue of quantitative regulation of endogenous Robo by Sdc, we turned to tissue culture. We demonstrate an effect of Sdc on endogenous Robo distribution in human MCF-7 cells ( Figure 4H ). Specifically, we find more Robo in the membrane, and thus presumably active, fraction under Sdc knock-down conditions. We also obtained similar data in Hela cells (not shown). If the Sdc-related change in Slit/Robo signaling is due to a change in Robo distribution rather than absolute levels, this would explain why we could not detect change in embryonic stainings.
3)
If Sdc levels do affect Robo2 levels in the dorsal branch, do they also affect the levels of Robo in the remaining tracheal system -as shown by Englund et al.? Furthermore, it would highly interesting to investigate if the cytoplasmic domain of Sdc is important for that function. These experiments are easy to do -tracheal specific expression of sdc variants followed by an antibody staining .
Answer: Since we did not observe differences in the Robo2 antibody staining experiments, those experiments were not performed.
Minor Points
In general the figure legends are extremely short and do not explain all details shown. Furthermore, at least in the combined pdf (text with figures) many panels are not labelled, I guess that this is an error from the generation of the pdf file.
Answer: We revised all figure legends to make them more complete. Answer: The triple allele "Rac1J10,Rac2 ,Mtl " replaced "rac" in the Figure 4G . 6 more important, the authors invested a lot of work to generate a new sdc allele and they compare the viability in trans of many published alleles. However, for the phenotypic analysis of the tracheal development they use two homozygous alleles. Based on the problem of potential additional hits on mutant chromosomes, I would strongly recommend to investigate phenotypes using two independent alleles in trans. Therefore, I would suggest to count the dorsal branch fusion defects in sdc[23]/sdc[2639] mutant larvae.
Answer: The fusion defect in sdc23/sdc2639 transheterozygotes has been quantified (4.1+/-0.47, not different from the homozygous mutants) and the result was added to Figure 2B .
7
The authors show a cell-autonomous function of Sdc within the tracheal cells, however the authors do not show tracheal expression of Sdc, I would suggest to include an antibody staining proving the presence of Sdc within the dorsal branch cells Answer: To avoid unspecific staining and because our Sdc antibody is Methanol-sensitive and therefore excludes usage in fixed embryos, we imaged stage 14 FlyTrap line CC00871 embryos, bearing a GFP cDNA insertion in the endogenous sdc locus on Chromosome 2, giving rise to a viable line expressing a correctly spliced Sdc-GFP-Sdc fusion protein expressed from the endogenous locus (see Supplementary Figure 3A for reversely transcribed cDNA sequencing: GFP is inserted between sdc exon 2 and 3 in the correct orientation and maintaining the correct frame). Confocal image analysis of CC00871 embryos demonstrates ubiquitous Sdc expression including the tracheal system and in the dorsal branch thereof ( Supplementary Figure 3B) , while the control line without GFP showed no signal under the same confocal settings (not shown).
Referee #3:
If the authors address the major points outlined below, I believe the manuscript could be accepted following re-review.
Major points: 1. There are some unexplained inconsistencies in the data that make the interpretation of their results difficult. For example, in Figure 3B , the frequency of DA missing is approximately 4 using p127-Gal4 driving Sdc RNAi. Figure 3D also shows approximately 4 DA missing per larvae using Btl-Gal4(3-1) driving Sdc RNAi, just like the phenotype found in Sdc2639 ( Figure 3E .) However in Figure 4 , Btl-Gal4(1) results in only 1.8 DA missing per animal (panel A) or 3.4 missing per animal (panel G). Two important questions need to be addressed in manuscript. First, what is different about the Btl(3-1) used in Figure 3D and Btl(1) used in Figure 4 that would result in this difference in phenotype? Second, and more importantly, why are the frequences of the defects in panel4A and 4G different when the experiment appears to be identical? This is an important point, because if the data from 4A were shown in panel 4G (which are described to the reader as the same experiment) it would inficate that rac is not a genetic interactor. Figure 3B is due to the sum of the effect of Sdc knockdown and the effect of the driver (p127-Gal4) alone, which is not the case for btl-Gal4 (3-1), a driver that does not have an effect by itself (see first bar in Figure 3D ). The experiments displayed in Figure 4A and 4G are different from all other experiments with pantracheal knockdown, because here not btl-Gal4(3-1) but the weaker btl-Gal4(1) driver line was used, resulting in weaker Sdc knock down. Also, in Figure 4A 25∞C instead of 28∞C incubation temperature were used (as stated in the Figure legend) , causing a less strong knock down due to the temperature sensitivity of the Gal4/UAS system. The reason why we performed the experiments in such a way in Figure 4A was that we wanted to obtain only partial/intermediate Sdc knockdown, in order to be able to detect both suppression or enhancement of the phenotype. This may not have been possible with a complete knockdown that is not sensitive to further enhancement. To make this more clear to the reader, we added a sentence on page 7: "we combined an intermediate Sdc knockdown with a loss-of-function allele in heterozygosity, either of the ligand Slit or of the receptor Robo2" The weaker btl-Gal4(1) was also used in Figure 4G , because it was easier to combine the three genetic elements driver, responder and mutant. To make to data more comparable within the manuscript, we created new combined stocks and repeated the experiments with btl-Gal4(3-1). We obtained similar results and replaced the old data with btl-Gal4(1) in Figure 4G . 2. The model put forth, that Sdc acts as a negative regulator of Slit/Robo signaling (presumably via Sdc's ability to reduce Robo expression levels), is modestly supported by the experimental data, but additional experiments could help substantiate this model. For example, a UAS-Sdc construct would be hypothesized to enhance the UAS-Comm phenotype (as both would be acting to limit Robo cell surface expression). In addition, if Sdc is indeed suppressing the Slit/Robo signaling pathway, overexpression of Sdc should result in a phenotype similar to Slit or Robo. Both of these experiments would provide support for the proposed model. The data showing that Sdc RNAi generates a phenotype similar to Slit or Robo loss of funciton, suggests that Sdc works with Slit and Robo to enhance Slit/Robo signaling. This seemingly conflicting evidence may be due in part to the apparent similarity between robo loss-of-function and robo gain-of-function phenotypes (both of which result in an increase in the number of DA missing per animal). If the authors want to propose a model in which Sdc suppresses Slit/Robo signaling as the cause of the DB defects, substantial revisions of Figure 4 are necessary, for example, by proposing a mechanism by which Sdc and robo, despite having similar mutant phenotypes could somehow suppress each others' activities.
Answer: The relatively high level of non-fusion with the fusion cell-specific p127>Sdc-RNAi in
Answer: We analyzed the effect of Sdc overexpression alone, or in combination with comm overexpression, on DB fusion. The data was added to Figure 3D and 4D, respectively. In both cases, additional Sdc did not have an effect, as we would predict for a coreceptor and the fact that the cytoplasmic domain is not required for Sdc function in DB fusion: if present in sufficient amounts, it fullfills its role, but if lacking, signaling is distorted. The only exception to that is overexpression of Robo2. Here, endogenous levels of Sdc might not be sufficient anymore and Sdc overexpression is needed to account for that ( Figure 4B ). For the tracheal system we suggest that Sdc stabilizes Slit/Robo signaling by reducing Robo protein levels. We support this by several lines of evidence. At the protein level, we show that when Sdc is reduced, Robo levels increase ( Figure 4F-G and new figure 4H with endogenous Robo levels). This is confirmed genetically by the fact that Robo overexpression alone gives rise to a phenotype that is exacerbated by Sdc loss and suppressed by Sdc overexpression (Figure 4C and D) . Similarly, overexpression of Commissureless gives rise to a phenotype that is suppressed by Sdc loss ( Figure  4E ). Reduction of the Slit dosage improves the Sdc-loss phenotype, both in Sdc knock down and mutant experiments ( Figure 4A and new Figure 4B ), indicating that Slit/Robo signaling is enhanced when Sdc is reduced. Our results do not exclude an additional role for Sdc in basic Slit/Robo signaling as it is known for Sdc from the nervous system, or heparan sulfate proteoglycans such as dally or dally-like in other tissues.
Minor Points: 1. In the x axis labels for Figure 3 , the font for delta gag and delta c is not correct.
Answer: The font in Figure 3 has been corrected 2. The y-axis needs labels in Figure 4F .
Answer: A y-axis label has been added in Figure 4F 3. In Figure legend 2C the authors state that "the arrow indicates the stub" but there is not an arrow in Figure 2C (or, perhaps it is in black in which case it should be in white).
Answer: Arrows have been added to Figure 2C . Figure legend 3C , the authors state that "Indicated are the absolute number or percentage of clones found in one of the three different DB cell types and whether these clones are part of a fused or unfused branch." This information is not in Figure 3C .
In
Answer: The information belongs to Table III and has been deleted in Figure lengend 3C . Figure legend 4g , the authors describe the influence of Rac levels on the Sdc RNAi DB phenotype, stating that they tested it "in combination with the rac1J10, Rac2, mtl" alleles. Only "rac" is shown in this figure.
Answer: The genotype has been corrected in Figure 4G . Thank you for the submission of your revised manuscript to our offices. We have now received the enclosed reports from the referees that were asked to assess it. While both referees acknowledge that the manuscript has been improved, they also still have a few suggestions that I would like you to incorporate before we can proceed with the official acceptance of your manuscript.
Referee 2 thinks that it needs to be clarified whether Robo and/or Robo2 are stabilized in syndecan mutants and whether Robo expression can be detected in the dorsal branches of these mutants. The referee also indicates that Robo gain of function should be quantified in the sdc mutants. Referee 3 feels that a possible mechanism for the rescue of the DB fusion phenotype by sdc expression in a single FC needs to be discussed and that the Rac data should be removed from the manuscript. Given that the current character count is too high, I think removal of the Rac data may also help in shortening the manuscript. I further would like to add that a definition for the error bars and that the number of the independent experiments performed need to be included in the legends for figures 2, 3 and 4. Also, scale bars need to be added to the microscope images in figure 4 , SF1, 2 and 3.
I have seen that you have changed the title of the manuscript, please check whether this is correct, as it currently says that syndecan stabilizes Robo levels, which is in contrast to the results of increased Robo levels in syndecan loss of function mutants.
I look forward to seeing a new revised version of your manuscript as soon as possible.
Yours sincerely,
Editor EMBO Reports
REFEREE REPORTS:
The revised manuscript of Schulz et al. is clearly improved. However, the central question, if sdc is affecting a robo2 loss of function phenotype or if sdc is causing a robo2 gain of function phenotype is -to my point of view -not answered without a doubt. The problem is, that according to the authors robo2 gain of function and loss of function result in an identical phenotype, although the authors do not include any pictures or numbers for the robo2 mutant situation. So a distinction based on the precise phenotype seems to be impossible. Furthermore, according to the detailed analysis of Englund et al., robo and robo2 have independent if not opposing functions in the ventral and presumably also in the dorsal branch formation (Robo as an repulsive Slit receptor and Robo2 as an attractive Slit receptor), so any change in the activity of one of the receptors will also affect a the activity of the other. Therefore, only genetic interaction experiments help to distinguish between the two models. The observed suppression of the sdc phenotype by the reduction of slit dosis favors the model that indeed the loss of sdc would cause a robo2 gain of function phenotype -as robo2 is the essential Slit receptor in the dorsal branch (robo had no loss of function phenotype; Englund et al). But surprisingly a reduction of robo2 dosis does not suppress the sdc phenotype. Furthermore, the authors do not see a change in the Robo2 protein levels in the sdc mutant, but the authors do see in two heterologous systems that a RoboGFP is stabilized in sdc mutants. Why did the authors investigate the stability of Robo and not of Robo2, which they suppose to be regulated by Sdc levels? From my point of view the results indicate, that Robo2 levels are not affected but the Robo levels are (at least in a heterologous system).
Furthermore, the authors strengthen their point that the Sdc controls Robo2 levels by investigating the Robo2 gain of function phenotype in sdc mutants and in sdc overexpressing embryos. However they did not investigate if sdc levels would also affect Robo gain of function causing is similar phenotype (Fig. 4c) Therefore, I would suggest to include 3 points to the manuscript before acceptance:
1) Is Robo2GFP stabilized by sdc loss of function as well ( cell culture )?
2) To analyze if Robo expression is now detectable in sdc mutants in the dorsal branches which according to Englund et al is not detectable in wt 3) To include the numbers of Robo gain of function in sdc mutants and together with UAS sdc as done for UAS robo2
Referee #3:
In this manuscript, Schulz et al provide the first evidence that the transmembrane HSPG Syndecan is involved in tracheal development in Drosophila, and that the role of Sdc in the migration and fusion of the dorsal branch cells is independent of Sdc's cytoplasmic domain. In addition, Schulz et al describe the generation of several novel Sdc mutations which represent the first alleles of Sdc that do not affect the neighboring gene sara. These are novel and significant findings, and through careful dose-sensitive genetic interaction data, the authors present a convincing case that Sdc acts as a negative regulator of Slit/Robo2 signaling in this system. In the revised version of the manuscript, the authors have addressed the concerns raised in the first review thoroughly, but there remain two recommendations for revisions.
1: The fact that restoration of Sdc expression in a single FC (in an otherwise Sdc mutant larvum) can completely rescue the DB fusion phenotype (an activity that requires the coordinated activities of both FCs) seems at odds with a strict cell-autonomous function for Sdc. In fact, this seems to suggest that there may be a cell non-autonomous function of Sdc in that Sdc expression in one FC can induce appropriate navigation and fusion of the contralateral FC. The authors should address a possible mechanism for this in their discussion.
2: The evidence for Rac involvement downstream of Sdc is very weak, does not substantially contribute to the model and should be removed from this manuscript. Control experiments are not shown for Figure 4I , the contribution of Rac signaling is not discussed, and the paper presents a coherent model without these data.
Minor Points: P2 -"stabilize the rac pathway" is vague P3 -last line -"signaling and this independently" should be "signaling and functions independently" P5 -line 20 -"While the number of terminal branches was not significantly reduced in sdc DB..." This is a bit vague. First, in the paragraph above, these are called "terminal extensions" (I assume they are the same thing). Second, it is unclear what the authors are referring to by "sdc DB". It might be clearer to state that "While the number of terminal extensions was not significantly reduced in sdc2639..." In addition, because there is a significant reduction in the number of TCs in this mutant, I assume the authors are referring only to segments in which TCs were found. If this is the case, it should be made clear. P. 17 - Figure legend 2D . The x-axis needs a label, "(filled diamants)" should be "(filled diamonds)" and DB5 should be defined. P. 17 -Figure legend 3C line 3 "a 3. instar lavae" should be "a 3rd instar larvae".
2nd Revision -authors' response 14 June 2011
Reviewer 2
Reviewer 2 suggested clarifying 3 points prior to acceptance 1) Is Robo2:GFP stabilized by sdc loss of function as well (cell culture )?
Answer: In the overexpression experiments performed in salivary glands, we used Robo:GFP and not Robo2:GFP, because only the former was available (Dr. Barry Dickson, Keleman et al. 2005) . Given the short amount of time allowed for the revision, we were not able to perform the suggested experiments. However, the results obtained for suggestion 3 (see new Figure 4C ), together with the original data from Figure 4C , similarly suggest that both Robo and Robo2 interact similarly with sdc when overexpressed. Regarding the mammalian cell culture experiments the reviewer refers to, these were performed to detect endogenous Robo, since Robo is known to be expressed in the cells we used (Marlow et al. 2008, Cancer Res), a good antibody was available, and there is no clear orthology between the fly and mammalian Robos (see phylogenetic analysis of Robo family members in Dickson and Gilestro, Ann Rev Cell Dev Biol 2006) . Thus, there is no direct correspondence between Robo1 vs Robo2 in flies and Robo1 vs Robo2 in mammals. Therefore, detecting endogenously expressed Robo in mammalian cells, is the cleanest experiment we can perform in this context.
2) To analyze if Robo expression is now detectable in sdc mutants in the dorsal branches which according to Englund et al is not detectable in wt Answer: We performed those experiments and analyzed dorsal branches of sdc heterozygous and homozygous embryos by confocal imaging after staining with anti-Robo antibody (13C9, DSHB, originally from C. Goodman). We did not observe an increase in Robo levels in sdc mutants and added the images to the supplementary data, as new Supplementary Figure 4B .
3) To include the numbers of Robo gain of function in sdc mutants and together with UAS sdc as done for UAS robo2.
Reviewer 3
Reviewer 3 made 2 revision recommendations and pointed out a number of minor errors to be corrected.
Answer: Indeed, this is a good point. The sentence on page 6 describing these data has been changed as follows: "We found that DB fusion still occurred in 15 out of 16 unilateral sdc FC MARCM (Mosaic analysis with a repressible cell marker) clones (Lee and Luo, 1999) ( Figure 3C , Table III ), suggesting that Sdc may also act in trans on the contralateral FC.
Answer: The Rac data has been removed.
Minor Points:
P2 -"stabilize the rac pathway" is vague Answer: The statement has been removed.
P3 -last line -"signaling and this independently" should be "signaling and functions independently"
Answer: The sentence has been changed to "signaling and functions independently".
P5 -line 20 -"While the number of terminal branches was not significantly reduced in sdc DB..." This is a bit vague. First, in the paragraph above, these are called "terminal extensions" (I assume they are the same thing).
Answer: The sentence has been changed to "terminal extensions".
Second, it is unclear what the authors are referring to by "sdc DB". It might be clearer to state that "While the number of terminal extensions was not significantly reduced in sdc2639..." In addition, because there is a significant reduction in the number of TCs in this mutant, I assume the authors are referring only to segments in which TCs were found. If this is the case, it should be made clear.
Answer: The sentence has been changed to "While the number of terminal extensions was not significantly reduced in sdc2639 in segments in which TC were found".
P. 17 - Figure legend 2D . The x-axis needs a label, "(filled diamants)" should be "(filled diamonds)" and DB5 should be defined.
